Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient’s cells instead of using drugs or surgery.
Researchers at Children's Hospital of Philadelphiahave developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant (HSCT).
The future treatment of individuals with various eye diseases could benefit immensely from a potential new gene therapy strategy, according to Trinity University researchers.
An anti-aging gene discovered in a population of centenarians has been shown to rewind the heart's biological age by 10 years.
Researchers at the University of Toronto and New York University have developed a novel technology that can engineer proteins to target any stretch of DNA in the human genome, opening a door toward gene therapies for a broader range of health conditions.
The first simple production of customizable proteins known as zinc fingers to treat diseases by turning genes on and off might be enabled with the help of an artificial intelligence (AI) program.
New company created to enable commercial manufacture of new cell and gene therapies.
The Drs Ayeez and Shelena Lalji & Family ALS Endowed Award for Innovative Healing was given to Clive Svendsen, PhD, a pioneer in regenerative medicine, for his significant contributions to the field of amyotrophic lateral sclerosis (AL) at Massachusetts General Hospital’s Sean M. Healey & AMG Center for ALS.
Scientists from the Massachusetts Institute of Technology (MIT) have come up with a new tool that has the potential to detach faulty genes and exchange them with new ones in a highly safe and effective way.
Technology developed by researchers at the Indiana University School of Medicine that can change skin tissue into blood vessels and nerve cells has also shown promise as a treatment for traumatic muscle loss.
Researchers from Johns Hopkins Medicine claim to have successfully “slid” genetic instructions into a cell and produced essential proteins that were lacking from those cells using a cell’s normal process for creating proteins.
A fault in cells that form a key part of the immune system can be repaired with a pioneering gene editing technique, finds new research demonstrated in human cells and mice, led by UCL scientists.
For gene therapy, the blood-brain barrier (BBB) poses a formidable obstacle. The BBB, which is made up of cells that are closely packed together, prevents poisons and pathogens from accessing brain tissue while also blocking potential treatments for diseases that impact the CNS.
Adults with a genetic form of childhood-onset blindness experienced striking recoveries of night vision within days of receiving an experimental gene therapy, according to researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania.
Astrea Bioseparations (“Astrea Bio”), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO™ lentiviral vector (LVV) purification technology.
Worldwide clinical studies for gene therapy utilizing CRISPR/Cas9 gene editing are now underway for a number of disorders. A study from Boston Children’s Hospital that was released in Nature Communications on June 27th, 2022, alerts readers to a possible CRISPR editing risk that has not yet been identified.
Healing debilitating genetic diseases is one of modern medicine’s most difficult challenges.
Cas7-11, the first CRISPR enzyme that can make precise, directed cuts to strands of RNA without hurting cells, was identified and described last year by researchers at MIT’s McGovern Institute for Brain Research.
CRISPR has marked the beginning of a new era in genomic medicine. The popular CRISPR-Cas9 has generated plenty of potent methods for curing genetic diseases.
Small interfering RNAs, or siRNAs, have the potential to cure tumors by targeting knocking down oncogenes that drive tumor development while avoiding the damage associated with chemotherapy.
MIP Diagnostics, a leading UK nanotechnology firm has today rebranded to MIP Discovery as the business continues its expansion within the healthcare sector.